Table 4.
Different combinations of modified MMSP markers observed in NPC samples selected on the basis that they were EBV (EBNA1)-positive (n = 36) and non-cancerous controls (n = 18) from Morocco
| Marker genes/combinations | 1 | 2 | 3 | 4 | 5 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| EBNA1 | + | + | + | + | + | + | + | + | + | + | + |
| U-LMP1 | - | + | - | + | + | - | - | + | + | - | + |
| M-ITGA9 | - | - | - | + | - | + | - | + | - | + | + |
| M-RASSF1A | - | - | - | - | + | + | + | + | + | + | + |
| M-P16 | - | - | + | - | - | - | + | - | + | + | + |
| NPC samples (n = 36) | 1 | 4 | 1 | 2 | 3 | 2 | 2 | 6 | 5 | 4 | 6 |
| Control (n = 18) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBNA1 + at least 3 methylation markers | Sn: 58 % (21/36) | ||||||||||
| Sp: 100 % (18/18) | |||||||||||
| EBNA1 + at least 2 methylation markers | Sn: 83 % (30/36) | ||||||||||
| Sp: 94 % (17/18) | |||||||||||
| EBNA1 + at least 1 methylation marker | Sn: 97 % (35/36) | ||||||||||
| Sp: 94 % (17/18) | |||||||||||